Do some promising COVID-19 vaccine candidates use nanotechnology?
Two promising COVID-19 vaccine candidates employ extremely small particles to induce human cells to ward off the disease, an application of nanotechnology. Nanotechnology involves physical particles about 1 to 100 nanometers in size. There are 25,400,000 nanometers in an inch.
Vaccines developed by Pfizer and Moderna, which have shown encouraging results in early human trials, use a "messenger" RNA nanoparticle, a molecule that conveys genetic information, to instruct cells to produce antigens. Antigens in turn induce the body's immune system to produce antibodies against the virus. An mRNA vaccine differs from widely-used "live" vaccines used to protect against a range of familiar diseases such as chickenpox and measles, which inject a weakened version of the targeted virus into the body.